ITI Life Sciences, a division of ITI Scotland Ltd., focuses on driving
innovation in the Life Sciences sector.
ITI Life Sciences seeks to fund research and development opportunities
which will contribute to an innovative Gene & Genome Synthesis
and Assembly programme.
The goal of this programme is to develop innovative tools, strategies
and methods that enable Gene & Genome Synthesis and Assembly.
ITI seeks innovative approaches that will impact the synthetic biology
and genome research fields by making gene & genome scale synthesis
readily available to a broad researcher base. To reach this goal, proposed
innovations should afford simplification and integration, short turnover
time, high accuracy and cost reduction compared to current methodologies.
ITI wishes to discuss innovative responses that seek to achieve this
goal by addressing SOME OR ALL of the key activities relating to Gene & Genome
Synthesis and Assembly. ITI is also interested in the use of enabling
technologies arising from other fields such as microfluidics.
As a general guide for this type of opportunities, ITI Life Sciences
usually commissions programmes in the range of £2-5 million ($4-10
million) with average lifetime of 18 – 36 months.
Responses are invited from companies, agencies, institutes,
consortia, academia and individuals. No geographical restrictions
apply and ITI welcomes responses to this call from non-UK organisations.
ITI is committed to helping our partners achieve success and ensuring
the successful onward commercialisation of programme outputs.
All relevant information relating to the Call can be downloaded from
the link below:
Download Call Document
(PDF 480KB)
To submit a response to the Call please complete the template found
at the link below:
Download
Response Template (Word 140KB)
Call responses should be emailed to SYB@itilifesciences.com no
later than the May 5, 2008.
To date, ITI Life Sciences has invested over £50 million in 5 research
programmes in the fields of stem cell technologies, text mining, transgenic
screening and safety models, cardiac biomarkers and lifetime fluorescence
assays. Most recently ITI has instigated a drug discovery programme
focused on Ubiquitin Signalling.
We have a proven track-record of working with entrepreneurial
companies and academic groups to create real innovation with a commercial
focus by crafting exciting collaborative programmes.
Please direct all questions regarding this call to nicolas.peyret@itilifesciences.com